Obsidian Therapeutics, Inc. OBX
Set alert
14.49 USD +0.06 +0.40%
As of Nov 3, 11:04 AM ET
14.00 Day range 14.97
11.77 52-week range 35.00
- YTD
- -17.21%
- 1 year
- -17.21%
- Open
- 14.23
- Prev close
- 14.43
- Mkt cap
- 894.47M
- Vol
- 135.06K
- Avg vol
- 395.13K
- EPS
- -1.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.00
- High
- 14.97
- Forward P/E
- -7.98
- Beta
- 2.60
- Short ratio
- 0.69
- Inst. own
- 27.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 31, 2025
- 50-d avg
- 19.99
- 200-d avg
- 19.99
- 1y target
- 39.00
6M chart
Events in this range
- Aug 5, 2026Rating: Piper Sandler · — → Overweight
- Aug 18, 2026Rating: LifeSci Capital · — → Outperform
- Aug 28, 2026Earnings: -1.38; estimate -1.63; surprise 15.34%
- Sep 9, 2026Rating: William Blair · — → Outperform
- Sep 22, 2026Rating: Leerink Partners · — → Outperform
Signals (4)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 4 weeks ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.00 +169.2% upside
Now 14.49
- Target (low)
- 32.00
- Target (mean)
- 39.00
- Target (high)
- 43.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.44 | -0.47 – -0.41 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Next quarter | -0.555 | -0.61 – -0.50 | 0.00 | 0.0% | 0 | 0.0% | 2 |
| Current year | -2.24 | -2.62 – -1.85 | -2,057.27 | +99.9% | 0 | 0.0% | 2 |
| Next year | -2.79 | -3.85 – -2.13 | -2.24 | -24.8% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | Leerink Partners | Initiated | — | Outperform |
| Sep 9, 2026 | William Blair | Initiated | — | Outperform |
| Aug 18, 2026 | LifeSci Capital | Initiated | — | Outperform |
| Aug 5, 2026 | Piper Sandler | Initiated | — | Overweight |
